Immunotherapy Plus Chemoradiotherapy Triples Survival in Esophageal Cancer Study
A propensity score matched study from Taiwan finds that adding the immunotherapy drug nivolumab to definitive chemoradiotherapy tripled median overall ...
A propensity score matched study from Taiwan finds that adding the immunotherapy drug nivolumab to definitive chemoradiotherapy tripled median overall ...
Researchers in Leipzig corrected a hidden error in a Bayesian network and found the transparent AI model matched real tumor ...
A phase 2 trial found that the HDAC inhibitor entinostat combined with nivolumab produced no tumor responses in advanced cholangiocarcinoma, ...
A systematic review of 116 case reports reveals that immune checkpoint inhibitors can trigger rare but often fatal heart complications, ...
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
A Japanese study found that immune-related adverse events during checkpoint inhibitor therapy for advanced gastric cancer were independently linked to ...
The Phase III LONESTAR trial found that adding radiation or surgery after nivolumab plus ipilimumab did not improve survival in ...
A 12-year Japanese database study of 16,573 patients shows first-line nivolumab plus chemotherapy rapidly displaced cisplatin-based regimens in HER2-negative advanced ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine